Results 1 to 10 of about 55 (29)
A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients [PDF]
ERJ Open ResearchBackground Macrolide antibiotics have immunomodulatory activity and taken chronically reduce exacerbations of COPD. However, chronic use can cause bacterial resistance. EP395 (glasmacinal), a novel macrolide, is being developed as a treatment to reduce exacerbations of COPD without inducing antimicrobial ...
Stephanie Korn +2 more
exaly +5 more sources
ePoster, 2019 Introduction/Background Cervical carcinoma is the most common gynecological malignancy during pregnancy. The incidence is expected to increase due to the fact that women delay childbearing. In this case report, we present a patient diagnosed with cervical carcinoma during 6 weeks pregnancy.
Mustafa Şahi̇N
exaly +3 more sources
Crabgrass Biology and Management in Turf
EDIS, 2009 This is part of the Weed Biology and Management in Turf series by J. Bryan Unruh, Darcy E. Partridge-Telenko, Barry J. Brecke, and Ramon Leon that highlights key facts about each weed, and include herbicide options for each variety of Florida turfgrass ...
Darcy E. Partridge-Telenko +3 more
doaj +8 more sources
The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung [PDF]
LungJennifer A Kricker +2 more
exaly +4 more sources
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 2020 [PDF]
Hemasphere, 2020 HemaSphere, Volume 4, Issue S1, Page 1-1168, June 2020.
europepmc +2 more sources
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation
Pulmonary Pharmacology and TherapeuticsMacrolide antibiotics have been shown to reduce exacerbations of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. This effect is believed to be due to the immunomodulatory properties of macrolides rather than their antimicrobial activity.
Jennifer A Kricker, Clive P Page
exaly +3 more sources
Pulmonary Pharmacology and TherapeuticsEpithelial barrier failure, a feature of several inflammatory lung diseases, contributes to exacerbations and disease progression. Acute exacerbations are often treated with macrolides, including azithromycin (AZM). In part, this is due to both primary antimicrobial and additional immunomodulatory actions, complemented by recently reported enhanced ...
Jennifer A Kricker
exaly +3 more sources
Pulmonary Pharmacology and TherapeuticsEP395, a macrolide with negligible antimicrobial activity but with anti-inflammatory effects in murine lipopolysaccharide (LPS) challenge model, is being developed as a potential treatment to reduce COPD exacerbations. This double-blind, placebo-controlled clinical study evaluated the pharmacodynamics of EP395 in response to inhaled LPS, an established
Jens M Hohlfeld +2 more
exaly +3 more sources
British Journal of Clinical PharmacologyAbstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug ...
Dave Singh
exaly +2 more sources
EHA2021 Virtual Congress Abstract Book
, 2021 HemaSphere, Volume 5, Issue S2, June 2021.
wiley +1 more source